For Many Lung Cancer Patients, Keytruda Is a Better Initial Treatment Than Chemotherapy, Study Finds

June 6, 2018

(Los Angeles Times) – In findings that may allow many lung cancer patients to avoid chemotherapy, a large clinical trial has shown that the immunotherapy drug Keytruda is a more effective initial treatment for two-thirds of patients with the most common type of lung cancer. Compared with advanced small-cell lung cancer patients who got chemotherapy, those treated first with Keytruda had a median survival time that was four to eight months longer.

Recommended Reading